Table 1.

Baseline characteristics of study subjects

	Phase 0–I	Phase II	Total
N	25	31	56
Age, year
Median	58	54	56
Range	42–77	24–69	24–77
Gender, no. (%)
Male	19 (76)	24 (77)	43 (77)
Female	6 (24)	7 (23)	13 (23)
KPS status
Median	90	90	90
Range	60–100	60–100	60–100
MMSE
Median	29	29	29
Range	15–30	20–30	15–30
Steroids, no. (%)
Yes	15 (60)	8 (26)	23 (41)
No	10 (40)	23 (74)	33 (59)
Pre Avastin, no. (%)
Yes		8 (26)	8 (26)
No		23 (74)	23 (74)

Phase 0 indicates the feasibility cohort (N=6).